Chitosan-based systems for intranasal immunization against foot-and-mouth disease

Pharmaceutical Development and Technology

Volumn 19, Issue 2, 2014, Pages 181-188

  Çokçalişkan, Can ^a   Özyörük, Fuat ^a   Gürsoy, R Neslihan ^b   Alkan, Musa ^a   Günbeyaz, Merve ^b   Cigdem Arca H ^b   Uzunlu, Ergun ^a   Şenel, Sevda ^b  

^a Plant Protection Research Institute   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cattle; Chitosan; Foot and mouth disease; Guinea pig; Intranasal immunization; Mucosal immunization

Indexed keywords

CHITOSAN; FOOT AND MOUTH DISEASE VACCINE; FREUND ADJUVANT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INACTIVATED VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; EXPERIMENTAL GUINEA PIG; FOOT AND MOUTH DISEASE; FREEZE DRYING; GEL; HOLSTEIN-FRIESIAN CATTLE; IMMUNE RESPONSE; IMMUNIZATION; MUCOSAL IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TARGET ORGANISM; VIRION; VIRUS NEUTRALIZATION; VISCOSITY; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; CHITOSAN; DRUG CARRIERS; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GUINEA PIGS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRAL VACCINES; VIRION;

EID: 84899785840     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.763263     Document Type: Article

References (49)

1. Tsuda T, Namba K, Yamasaki Y, et al. Quantitative single radial immunodiffusion of foot-and-mouth disease viral antigens using convalescent cattle sera. Nippon Juigaku Zasshi 1987;49:461-8.
2. Radostits OM, Blood DC, Gay CC. Veterinary medicine: a textbook of the diseases of cattle, sheep, pigs, goats and horses. London: Bailliere Tindall; 1994.
3. Alexandersen S, Zhang Z, Donaldson AI. Aspects of the persistence of foot-and-mouth disease virus in animals: the carrier problem. Microbes Infect 2002;4:1099-110.
4. Hedger RS, Condy JB. Transmission of foot-and-mouth disease from African buffalo virus carriers to bovines. Vet Rec 1985;117:205.
5. Chinsangaram J, Moraes MP, Koster M, Grubman MJ. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J. Virol 2003;77:1621-5.
6. Fischer D, Rood D, Barrette RW, et al. Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge. J Virol 2003;77:7486-91.
7. van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 2000;6:123-32.
8. Amidi M, Romeijn SG, Verhoef JC, et al. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 2007;25:144-53.
9. Illum L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51:81-96.
10. Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation. J Pharm Sci 2000;89:850-66.
11. Arca HC, Gunbeyaz M, Şenel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009;8:937-53.
12. Senel S. Chitosan based particulate systems for non-invasive vaccine delivery advances in polymer science. Vol. 239. Berlin: Springer 2011:1-28.
13. Şenel S, McClure SJ. Potential applications of chitosan in veterinary medicine. Adv Drug Deliv Rev 2004;56:1467-80.
14. Sutmoller P, Barteling SS, Olascoaga RC, Sumption KJ. Control and eradication of foot-and-mouth disease. Virus Res 2003;91:101-44.
15. Garmise RJ, Staats HF, Hickey AJ. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 2007;8:2-10.
16. Gordon S, Saupe A, McBurney W, et al. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. J Pharm Pharmacol 2008;60:1591-600.
17. Maxwell S, Şenel, S, McClure S. Chitosan for delivery of mucosal vaccines in ruminants. 33rd Annual Meeting and Exposition of the Controlled Release Society; 2006 Jul 22-29, Vienna, Austria.
18. Maxwell S, Şenel S, McClure S. Mucosal vaccination of sheep with heliotrine antigen. 13th International Pharmaceutical Technology Symposium; 2006 Sep 10-13; Ankara, Turkey.
19. Sayin B, Somavarapu S, Li XW, et al. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 2009;8:362-9.
20. Sayin B, Somavarapu S, Li XW, et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm 2008;363:139-48.
21. van der Lubben IM, Verhoef JC, Borchard G, et al. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001;52:139-44.
22. Wang X, Zhang X, Kang Y, et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 2008;26:5135-44.
23. Iyer AV, Ghosh S, Singh SN, et al. Evaluation of three 'ready to formulate' oil adjuvants for foot-and-mouth disease vaccine production. Vaccine 2001;19:1097-105.
24. Barteling SJ, Meloen RH. A simple method for the quantification of 140S particles of foot-and-mouth disease virus (FMDV). Arch Gesamte Virusforsch 1974;45:362-4.
25. Bahnemann HG. Inactivation of viruses in serum with binary ethyleneimine. J Clin Microbiol 1976;3:209-10.
26. OIE. Manual of diagnostic tests and vaccines for terrestrial animals. In: O.I.d.E. (OIE) ed. Foot and mouth disease, Vol. section 2.1, Chapter 2.1.5. Paris: OIE; 2008.
27. Hamblin C, Barnett IT, Crowther JR. A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. II. Application. J Immunol Methods 1986;93:123-9.
28. Ellis PR, James AD. The economics of animal health: (1) major disease control programmes. Vet Rec 1979;105:504-6.
29. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-53.
30. Baudner BC, Giuliani MM, Verhoef JC, et al. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 2003;21:3837-44.
31. Gunbeyaz M, Faraji A, Ozkul A, et al. Chitosan based delivery systems for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur J Pharm Sci 2010;41:531-45.
32. Kang ML, Kang SG, Jiang HL, et al. Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs. J Microbiol Biotechnol 2008;18:1179-85.
33. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 2004;216:71-4.
34. Şenel S. Chitin, chitosan, oligosaccharides and their derivatives biological activities and applications. Boca Raton (FL): Taylor & Francis; 2010.
35. Vila A, Sanchez A, Janes K, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004;57:123-31.
36. Kang ML, Jiang HL, Kang SG, et al. Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 2007;25:4602-10.
37. Hagenaars N, Mastrobattista E, Verheul RJ, et al. Physicochemical and immunological characterization of N,N,N-trimethyl chitosancoated whole inactivated influenza virus vaccine for intranasal administration. Pharm Res 2009;26:1353-64.
38. Song H, Wang Z, Zheng D, et al. A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine. Biotechnol Lett 2005;27:1669-74.
39. Challa S, Barrette R, Rood D, et al. Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus. Vaccine 2007;25:3328-37.
40. van Lierop MJ, Wagenaar JP, van Noort JM, Hensen EJ. Sequences derived from the highly antigenic VP1 region 140 to 160 of foot-and-mouth disease virus do not prime for a bovine T-cell response against intact virus. J Virol 1995;69:4511-14.
41. Bakke H, Setek TN, Huynh PN, et al. Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory. Vaccine 2004;22:2278-84.
42. McNeela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22:909-14.
43. Haneberg B, Dalseg R, Wedege E, et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998;66:1334-41.
44. Tamura S, Asanuma H, Ito Y, et al. Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice. Vaccine 1994;12:310-16.
45. Quan CP, Berneman A, Pires R, et al. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect Immun 1997;65:3997-4004.
46. Doel TR, Chong WK. Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. Arch Virol 1982;73:185-91.
47. Randrup A. Ultracentrifugation of the virus of foot-and-mouth disease: IV. Splitting of the greater complement-fixing particle. Acta Pathol Microbiol Scand 1954;34:366-74.
48. Burroughs JN, Rowlands DJ, Sangar DV, et al. Further evidence for multiple proteins in the foot-and-mouth disease virus particle. J Gen Virol 1971;13:73-84.
49. Saiz JC, Gonzalez MJ, Morgan DO, et al. Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes. Virus Res 1989;13:45-60.